semaglutide clinical trials The US Department of Veterans Affairs has launched a new trial to determine if could be used to treat alcohol abuse. 600 veterans with moderate to severe alcohol abuse disorder Efficacy of Oral Semaglutide: Overview

Semaglutide works by targeting the GLP-1 receptor

Phase 2 Obesity Trial The Phase 2 obesity trial published in the New England Journal of Medicine in 2023 randomized 338 adults without diabetes to receive Retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks

It is not approved for use as a drug, food, cosmetic, or medical product, and is not intended for human or animal consumption

The focus is on expanding access while maintaining affordable and competitive pricing

It documents the measured purity (HPLC), confirmed identity (mass spectrometry), and screening results such as bacterial endotoxin

These medications mimic the action of the hormone GLP-1 (glucagon-like peptide-1), which helps manage blood sugar levels by stimulating insulin release, reducing glucagon secretion, and slowing gastric emptying